ESR1 and breast cancer: Triple negative breast cancer (TNBC) accounts for 12–17% (depending on immunohistochemical cut-offs used) of all breast cancer patients and are defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).